Mater people

You are here:

Home > News and social media > June 2018 > Professor John Prins appointed Acting Group CEO at Mater

Professor John Prins appointed Acting Group CEO at Mater

Friday, 1 June 2018

Professor John Prins appointed Acting Group CEO at Mater

Newly appointed Acting Group Chief Executive Officer (CEO) at Mater Group, Professor John Prins, has shared his focus for his new role.

Taking over from Dr Shane Kelly, who commenced as CEO in 2015, Professor Prins said he is honoured to have been given the responsibility, following the enormous contribution made by Dr Shane Kelly.

“Dr Kelly established Mater Group as an integrated, singularly governed entity combining Mater Health, Mater Education, Mater Research and Mater Foundation. My focus is to build upon this foundation, with a strong emphasis on high quality performance, measured against international standards, across the Group,” said Professor Prins.

“We have a public and personal responsibility to ensure all patient care is of high standard and safe; that our education programs produce graduates in demand; that our research has broad clinical impact; and that our donors’ generosity is rewarded by efficient and purposeful use of funds.”

“We are immensely privileged to work ― and, for 700 of us, volunteer ― in an environment that is dedicated to improving the lives of others, and it’s important that we enjoy what we do!”

Prior to this role, Professor Prins was Chief Executive Officer of Mater Research and Director of MRI-UQ, and Professor of Endocrinology at the University of Queensland. He is actively involved in undergraduate and post-graduate teaching and training.

Professor Prins undertook his clinical training in endocrinology in Brisbane and completed a PhD in adipose tissue biology at The University of Queensland (UQ). His first postdoctoral research appointment was at the University of Cambridge, UK, based at Addenbrooke’s Hospital.

In 2004, Professor Prins founded the UQ Centre for Diabetes and Endocrine Research, which merged with the UQ Centre for Immunology and Cancer Research (CICR) in January 2007 to form the UQ Diamantina Institute. Professor Prins has continued parallel clinical, research and administrative activities.

Chair of the Mater Board, Brian Flannery, said Professor Prins is a well-known and valuable member of the Mater and Research communities.

“Professor John Prins is a clinician-scientist, a key opinion leader in diabetes and endocrinology in Australia and sits on numerous national and international scientific, clinical and educational committees and boards. He is an accomplished leader and we are delighted he has agreed to take this role.”

 

Public relations contacts

Phone number: 07 3163 8111 (ask for the on-call media officer)

Email: news@mater.org.au

Tags: Mater Group, Mater Group Executive